ArticleFrontiers in psychiatry2026
Circulating miR-1260a as a potential biomarker for First-Episode of Psychosis: a replication study in a treatment-Naïve Romanian cohort.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of first-episode psychosis (FEP) in adolescents and young adults remains primarily clinical, often complicated by symptom overlap and the heterogeneity of psychiatric presentations. There is a critical need for non-invasive, objective biomarkers to support early diagnosis and patient stratification. This study aimed to replicate a panel of 10 candidate microRNAs (miRNAs) identified in a previous exploratory study within a larger, independent cohort of treatment-naïve Romanian adolescents and young adults. This cross-sectional study included 50 participants (22 drug-naïve FEP patients and 28 age- and sex-matched controls). Total RNA was isolated from plasma, and the levels of miRNAs were measured using qRT-PCR. Clinical symptoms were assessed using standardized psychiatric scales (PANSS, HDRS, YMRS). We successfully replicated miR-1260a as significantly modified in the plasma of treatment-naïve FEP patients compared to controls (FDR Adj. p = 0.04). ROC analysis for miR-1260a yielded an AUC of 0.741 (p = 0.004). Furthermore, exploratory correlation analyses conducted exclusively within the FEP patient group indicated a negative correlation between miR-1260a levels and the positive PANSS score (p = 0.017, rho = -0.503), which did not retain statistical significance after FDR correction (FDR Adj. p = 0.102). Our results corroborate and enhance our prior exploratory research, highlighting miR-1260a as a prominent candidate among circulating biomarkers for early psychosis. Future longitudinal studies are necessary to evaluate the diagnostic, prognostic, and clinical monitoring efficacy of this miRNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.